Browsing Category
Ocular Delivery
Innovation in the Development of Synthetic and Natural Ocular Drug Delivery Systems for Eye Diseases…
Nowadays, ocular drug delivery still remains a challenge, since the conventional dosage forms used for anterior and posterior ocular disease treatments, such as topical, systemic, and intraocular administration methods, present important limitations mainly related to the anatomical complexity of the…
Read More...
Read More...
Ocular permeability, intraocular biodistribution of lipid nanocapsule formulation intended for…
Recently, cGMP analogues have been investigated for the treatment of inherited retinal degenerations (IRD) using intravitreal injections. However, higher vitreous elimination rates limit the possibility to treat the retina with small molecule drugs. Here, we investigated the potential of lipid…
Read More...
Read More...
Nanostructured Lipid Carriers Aimed to the Ocular Delivery of Mangiferin: In Vitro Evidence
Although mangiferin (MGN) is a natural antioxidant that could be a good candidate for the treatment of ocular diseases, its use in ophthalmology is strongly compromised due to its high lipophilicity. Its encapsulation in nanostructured lipid carriers (NLC) seems to be an interesting strategy for…
Read More...
Read More...
Development of a Liposomal Gel for Prolonged Ophthalmic Soluble Drug Delivery
Liposome, as a drug delivery vehicle, entraps drugs, releases them sustainably, and modifies release patterns. This entrapment has diminished exposure of the drug to the eye medium, which could minimize adverse effects. In this investigation, 18 formulations in 3 key categories (liposome, gel and…
Read More...
Read More...
Polymer- and Lipid-Based Nanocarriers for Ocular Drug Delivery: Current Status and Future…
Ocular diseases seriously affect patients' vision and life quality, with a global morbidity of over 43 million blindness. However, efficient drug delivery to treat ocular diseases, particularly intraocular disorders, remains a huge challenge due to multiple ocular barriers that significantly affect…
Read More...
Read More...
Overcoming Challenges in Ophthalmic Formulations through Polymer Selection
Ophthalmic drugs are delivered to the eye to treat chronic diseases such as dry eye and acute conditions such as inflammation and infections.
The market for drugs administered to the eye is growing, in large part, due to our aging population and the increased prevalence of eye-related conditions…
Read More...
Read More...
Cyclodextrin-enabled nepafenac eye drops with improved absorption open a new therapeutic window
Nepafenac is a highly effective NSAID used for treating postoperative ocular inflammation and pain after cataract surgery and its advantage over conventional topical NSAIDs has been proved many times. However, Nevanac® is a suspension eye drop, which clearly lacks patient compliance causing…
Read More...
Read More...
Ocular Drug Delivery: a Comprehensive Review
The human eye is a sophisticated organ with distinctive anatomy and physiology that hinders the passage of drugs into targeted ophthalmic sites. Effective topical administration is an interest of scientists for many decades. Their difficult mission is to prolong drug residence time and guarantee an…
Read More...
Read More...
Research progress of ophthalmic preparations of immunosuppressants
Immune ophthalmopathy is a collection of autoimmune eye diseases. Immunosuppressants are drugs that can inhibit the body’s immune response. Considering drug side effects such as hepatorenal toxicity and the unique structure of the eye, incorporating immunosuppressants into ophthalmic nanodrug…
Read More...
Read More...
Influence of PLGA End Groups on the Release Profile of Dexamethasone from Ocular Implants
The present study deals with the development of dexamethasone (DM)-loaded implants using ester end-capped Resomer RG 502 poly(lactic acid-co-glycolic acid) (PLGA) (502), acid end-capped Resomer RG 502H PLGA (502H), and a 502H:502 mixture (3:1) via hot melt extrusion (HME). The prepared intravitreal…
Read More...
Read More...